Connect with us

Technology

Three Scientists Honored with $250,000 Blavatnik Awards for Breakthroughs in Organic Chemistry, Gene Editing and Bioelectronics

Published

on

Celebrations held at the American Museum of Natural History in New York for the Blavatnik Awards for Young Scientists’ 20th anniversary gala.

NEW YORK, Oct. 7, 2026 /PRNewswire/ — Three exceptional scientists each received $250,000 – the largest unrestricted scientific award available to early-career scientists in the United States – at the 2026 ceremony of the Blavatnik Awards for Young Scientists for their work in organic chemistry, genome engineering, and bioelectronics.

Presented by the Blavatnik Family Foundation and The New York Academy of Sciences, the Awards honor America’s most innovative faculty-rank scientists and engineers, aged 42 and younger. The 2026 Laureates were selected from a highly competitive pool of 372 nominees representing 187 academic and research institutions across 43 states. From this national pool, an independent jury of eminent scientists also selected 15 Finalists who each received $15,000 in unrestricted funding.

The winners of the 2026 Blavatnik National Awards for Young Scientists are:

CHEMICAL SCIENCES LAUREATE:
David Nagib, The Ohio State University
Organic synthesis is a major bottleneck in the discovery of new medicines. To address this, organic chemist Prof. David Nagib develops methods to create key medicinal building blocks by harnessing reactive chemical species called radicals and carbenes. His lab has invented ways to activate inert portions of complex molecules. By turning high-energy chemistry into reliable methods, Nagib’s work helps chemists create more potent and selective medicines faster, cheaper, and more efficiently. These advances are accelerating pharmaceutical discovery and expanding what is possible in modern organic chemistry.

LIFE SCIENCES LAUREATE:
Patrick Hsu, Arc Institute and Stanford University
Biology relies on molecular machines that read, write, and regulate genetic information, yet scientists are only beginning to understand how to harness their full potential. Prof. Patrick Hsu, a bioengineer and co-founder of the Arc Institute, discovers and engineers these programmable biological systems to precisely manipulate DNA and RNA. His work has expanded the CRISPR toolkit with RNA-targeting enzymes, uncovered programmable bridge RNAs that can direct large-scale genome rewriting, and pioneered artificial intelligence models that predict and design biological sequences. Together, these innovations are transforming genome engineering, accelerating biological discovery, and supporting the development of new gene therapies while laying the foundation for a new era of AI-enabled biological design.

PHYSICAL SCIENCES & ENGINEERING LAUREATE
Jonathan Rivnay, Northwestern University
The human body runs on chemical and ionic signals, but ordinary electronics struggle to read or join that conversation. To overcome this obstacle, materials scientist and biomedical engineer Prof. Jonathan Rivnay is designing soft, flexible electronic materials that work directly with living cells and tissue. Rivnay has helped to pioneer implantable “living pharmacies”: small devices that hold engineered cells and prompt them to make and release medicines inside the body. Rivnay’s work is leading the world to more personalized treatments for long-term conditions such as cancer, diabetes, and circadian rhythm disorders.

“We are extremely proud to recognize this year’s National Laureates and to welcome them into the Blavatnik Awards community,” said Len Blavatnik, Founder of Access Industries and Head of the Blavatnik Family Foundation.

The Ceremony

The Blavatnik Awards announced the Laureates at its 20th anniversary gala, a black-tie awards ceremony held October 6 at the American Museum of Natural History, hosted by Len and Emily Blavatnik and presented by Robert P. Lifton, MD, PhD, President of The Rockefeller University.

During the ceremony, each Laureate shared their prize-winning research with leading figures in philanthropy, research, academia, business, and the arts. Fifteen Blavatnik National Award Finalists and nine Blavatnik Regional Awards honorees were recognized as well.

This year also marked a milestone for two institutions: The Ohio State University and the Arc Institute each celebrated their first-ever Blavatnik National Award Laureates.

Reflecting on the long-term impact of the Awards, Lifton listed the successes of the first cohort of scientists who received their Blavatnik Award twenty years earlier. “From this inaugural group of 14 honorees, eight now hold named and endowed chairs at institutions including Yale, Rockefeller, Cornell, Columbia and Cambridge. Five have been elected to the U.S. National Academy of Sciences, two to the National Academy of Medicine, six to the American Academy of Arts & Sciences and one to the Royal Society of the UK. And subsequent to their Blavatnik Awards, they’ve won prizes such as the Shaw Prize, the Benjamin Franklin Medal and even the Fields Medal.”

In his remarks, Professor Nicholas B. Dirks, President and CEO of The New York Academy of Sciences and Chair of the Awards’ Scientific Advisory Council, recalled the origins of the Blavatnik Awards. The idea was inspired by Len Blavatnik’s experience at the 2007 Nobel Prize ceremony, where the prestige of the occasion and the recognition of their lifelong discoveries prompted a question:

“What if exceptional scientists could be recognized earlier in their careers, at a pivotal moment when they were just beginning to build their own research programs, pursue ambitious scientific questions, and take creative risks? And so, twenty years ago, the Blavatnik Awards were born – a first-of-its-kind science prize dedicated to recognizing the most promising early-career scientists of their generation, administered by The New York Academy of Sciences.”

Since 2007, the Blavatnik Awards have honored 539 scientists and awarded $21.5 million in unrestricted funding. At a time when intense competition for research funding makes it increasingly challenging for early-career scientists to establish independent programs and pursue innovative ideas, the Awards provide unrestricted prize funding that gives recipients the freedom to explore high-risk, high-reward research.

Beyond the lab, Blavatnik Awards honorees are using science to drive global economic growth. To date, Blavatnik Awards honorees have founded 52 companies, six of which are publicly traded, and collectively valued at more than $40 billion.

About the Blavatnik Awards for Young Scientists: blavatnikawards.org/about/

About the Blavatnik Family Foundation: blavatnikfoundation.org/about-us/  

About The New York Academy of Sciences: nyas.org/about-us/ 

NOTE TO EDITORS: Select ceremony collateral, including imagery, videos, graphics, and headshots, can be found in the 2026 Blavatnik Awards Press Kit.

View original content to download multimedia:https://www.prnewswire.com/news-releases/three-scientists-honored-with-250-000-blavatnik-awards-for-breakthroughs-in-organic-chemistry-gene-editing-and-bioelectronics-302901042.html

SOURCE Blavatnik Family Foundation; The New York Academy of Sciences

Continue Reading

Technology

Infinitus Launches FieldForce to Extend the Reach of Pharmaceutical Sales and Reimbursement Teams

Published

on

By

AI agent solution helps field teams become AI first, preparing for HCP meetings, staying connected between visits, and extending provider and reimbursement support without adding additional headcount

SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ — Infinitus, healthcare’s agentic communications platform, today announced FieldForce, a new set of secure AI agents designed to extend the capacity of pharmaceutical field teams. Pharma companies can deploy FieldForce to support sales representatives, field reimbursement managers (FRMs), or both, depending on the needs of their organization. For both roles, FieldForce enables teams to become AI-first, using AI agents to extend their capacity across activities before, after, and in between HCP interactions. Importantly, it gives pharmaceutical companies another way to support more providers while giving HCPs access to information and assistance between field visits that can help them better serve their patients.

Pharmaceutical companies are under growing pressure to increase commercial productivity while managing costs. A May 2026 analysis from Deloitte found that sales representatives spend roughly two-thirds of their workday on activities such as research, product and prescribing information, scheduling, and administrative work, leaving less than one-third for customer interactions.

The pressure to do more with existing resources is also playing out across the industry. One recent analysis found that the 17 largest pharmaceutical companies collectively reduced their workforces by more than 22,000 employees in 2025, as companies looked to improve efficiency and prepare for patent expirations and other market pressures. FieldForce is specifically designed to help organizations like these extend field capacity without requiring a corresponding increase in headcount.

Supporting sales and reimbursement teams around HCP interactions

FieldForce gives sales representatives and FRMs agentic support to help manage the work around HCP interactions. The agents connect with field teams’ CRMs to pull together information for preparation before a meeting, capture notes, and update systems afterward. Additional FieldForce agents can be available for inbound calls 24/7 to support providers by answering questions between visits.

For FRMs, AI agents can answer questions about prior authorization status, claims and reimbursement, and help onboard provider offices with approved access materials. Across these interactions, Infinitus Lens provides same-day compliance monitoring and surfaces trends and insights, such as: prescribing trends per provider or provider tier; emerging question themes or support topics; and recommendations for proactive and compliant content or education that can be shared.

Extending provider reach without adding field headcount

FieldForce is also designed to help pharmaceutical companies support providers who may not have regular contact with a sales representative or FRM. A dedicated AI agent can be available between visits, giving providers a direct path to information and support when a field team member is unavailable. For HCPs, that can mean more timely access to information and reimbursement support as they work to help patients access and navigate their treatment. For pharmaceutical companies, it can expand coverage across a larger provider population without requiring a corresponding increase in field hires.

“Our pharma customers need their field teams to cover more providers while managing significant cost and productivity pressures,” said Ankit Jain, CEO and co-founder of Infinitus Systems. “They’re also seeing that the companies embracing AI are finding new ways to scale and operate more efficiently, making an AI-first approach increasingly essential to staying competitive. FieldForce gives sales and reimbursement teams AI support across the work that happens before, after and in between HCP interactions, extending their capacity so they can spend more of their time on the relationships and issues that require their attention.”

Connecting commercial and medical conversations safely

Infinitus FieldForce is built around the distinction between promotional and medical communications within pharmaceutical organizations. The sales agent can support appropriate promotional conversations with HCPs. When a provider asks a clinical or safety question that falls outside the sales representative’s role, the agent can hand the conversation off to a member of the organization’s Medical Information team along with full context. This gives HCPs a direct path to the appropriate resource while helping sales representatives stay within their role.

Built for pharmaceutical organizations

FieldForce brings Infinitus’s trusted, healthcare-native AI to power internal tools for the first time. AI agents are trained on specific data and resources provided by each individual pharma organization along with Infinitus’s proprietary knowledge graph that leverages historical data from millions of payor interactions. This gives pharmaceutical leaders a consistent source of approved information across provider engagement and reimbursement workflows, while providing a way to measure the impact of AI through metrics such as provider coverage, interactions, and cost per interaction.

In July, Infinitus announced its AI-first, human-backed hub solution, designed to streamline patient, provider, and payor communications traditionally managed through legacy call-center infrastructure. FieldForce extends Infinitus’s AI agent capabilities into pharmaceutical commercial and market access teams, giving sales representatives and FRMs around-the-clock support while helping HCPs get timely answers and support to help patients.

About Infinitus

Infinitus is healthcare’s agentic AI communications platform, coordinating conversations and workflows across providers, health plans, specialty pharmacies, pharmaceutical manufacturers, and patients to make sure care reaches those who need it. Infinitus’s system combines industry-leading safety guardrails with the largest dynamic knowledge graph built on millions of real-world interactions. The company has raised over $100M from investors including Google Ventures, Kleiner Perkins, Andreessen Horowitz, and Coatue. Infinitus was recently named to Fast Company’s World’s Most Innovative Companies and is trusted by over 50% of the Fortune 50 healthcare companies. Learn more at www.infinitus.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/infinitus-launches-fieldforce-to-extend-the-reach-of-pharmaceutical-sales-and-reimbursement-teams-302900497.html

SOURCE Infinitus Systems, Inc.

Continue Reading

Technology

JND AutoRedact™ Wins 2026 Relativity Innovation Award

Published

on

By

AutoRedact recognized for delivering redaction accuracy at scale inside Relativity aiR.

SEATTLE, Oct. 7, 2026 /PRNewswire/ — JND Legal Administration, the U.S. leader in legal management and administration services, announced that its AutoRedact™ AI-assisted redaction tool has received the Relativity Innovation Award in the Act category at Relativity Fest 2026, the premier event in the eDiscovery industry. The Act Award honors solutions that enhance Relativity’s redaction, quality control, reporting, case strategy, or production features, delivering meaningful results.

AutoRedact uses both AI and deterministic rules to find and redact sensitive information like personal data or privileged content within images stored in Relativity aiR (formerly RelativityOne). Legal teams describe in plain language what needs to be redacted, iterate and test the results on sample documents in the Detector Lab, and then apply the calibrated instructions at scale across their document populations. AutoRedact also has a dedicated detector for data subject access requests (DSARs) that redacts personal and sensitive information while keeping the requesting individual’s own data visible, a common and time-consuming challenge in privacy compliance. AutoRedact provides confidence levels for redactions to assist legal teams with focusing their human QC efforts and every redaction can be reviewed and adjusted before documents are produced.

“I’m incredibly grateful to our team, whose expertise and relentless testing made AutoRedact possible,” said Ben Sexton, Senior Vice President of Innovation and Strategy at JND. “We’re excited about what AutoRedact can do for our clients.”

“Innovation at JND has always meant building tools that deliver real, measurable results,” said Jennifer Keough, CEO and Co-Founder of JND. “AutoRedact reflects the ingenuity and dedication of our team, and this award is a testament to their work. We congratulate everyone who made it possible.”

Headquartered in Seattle, JND continues to solidify its status as the industry leader in end-to-end eDiscovery solutions. Its eDiscovery service line supports corporations, law firms, and government agencies in deploying the best solutions and technology to meet their goals using Relativity aiR, the market’s leading cloud-based technology solution. JND is one of only two Relativity Platinum Provider Partners.

This award marks JND’s second Relativity Innovation Award in three years. In 2024, Ben Sexton received the Relativity Innovation Award in the Artificial Intelligence category for his leadership in the adoption and development of generative AI tools in eDiscovery. JND’s team also includes three Relativity AI Visionary award recipients.

To schedule a demo of AutoRedact, contact autoredact@jndla.com.

About JND Legal Administration

JND eDiscovery, a RelativityOne software reseller and a division of JND Legal Administration, a Sedgwick company, is the nation’s foremost legal services and settlement administration solutions provider. JND’s fully-featured Relativity aiR instance and professional services team support a broad network of plaintiff and defendant law firms, corporate legal departments and government agency clients in future-proofing their eDiscovery systems. For more information, visit https://www.jndla.com/ediscovery.

Media Contact:
Joe Sexton
info@jndla.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/jnd-autoredact-wins-2026-relativity-innovation-award-302900438.html

SOURCE JND Legal Administration

Continue Reading

Technology

L8P8 Launches Tru8 Connect, Free Messaging That Uses Usernames Instead of Phone Numbers

Published

on

By

Messages are end-to-end encrypted, kept only on users’ phones and deleted after eight days

GLENDALE, Calif., Oct. 7, 2026 /PRNewswire/ — L8P8 Inc. today launched Tru8 Connect, a free messaging feature inside the Loop8 app for iOS and Android. People on Tru8 Connect find each other by username, so neither person ever sees the other’s phone number.

Giving someone your number is a bigger step than it used to be. A phone number can lead to your name, your address and the accounts tied to it. Once you hand it out, you can’t take it back. On Tru8 Connect, if a conversation goes badly, you block the person and that’s the end of it. They never had your number in the first place.

Messages are end-to-end encrypted. Loop8’s servers pass them along but can’t read them, and they delete each message once it’s delivered. After that, the message exists only on the two phones in the conversation, and opening it takes Face ID or a fingerprint. Every message deletes itself eight days after it’s sent.

When the app detects a screenshot or screen recording of a chat or a shared photo, it alerts everyone in the conversation and shows who took it.

“People think twice before giving a stranger their phone number, and they should,” said Zarik Megerdichian, founder and CEO of L8P8. “With Tru8 Connect, you don’t have to. And since we delete messages once they’re delivered, there’s no pile of old conversations sitting on our servers for someone to break into later.”

Tru8 Connect is open to users 16 and older. It’s available now in the Loop8 app, which is free on the App Store and Google Play. Loop8 also includes a password manager and an authenticator, both unlocked with biometrics instead of a master password.

About L8P8 Inc.
L8P8 Inc., based in Glendale, Calif., makes privacy and identity software that uses biometrics in place of passwords. Its products include Loop8, a consumer app, and Loop8ID, an age verification and identity platform for businesses. Learn more at loop8.ai and loop8id.com.

Media Contact
Zarik Megerdichian
L8P8 Inc.
pr@l8p8.com
‪(818) 208-0238‬

View original content to download multimedia:https://www.prnewswire.com/news-releases/l8p8-launches-tru8-connect-free-messaging-that-uses-usernames-instead-of-phone-numbers-302897892.html

SOURCE L8P8 Inc.

Continue Reading

Trending